Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia

Schizophrenia Research

Volumn 104, Issue 1-3, 2008, Pages 108-120

  Bauer, Deborah ^a,b   Gupta, Daya ^c   Harotunian, Vahram ^d   Meador Woodruff, James H ^a,b   McCullumsmith, Robert E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anterior cingulate cortex; Dorsolateral prefrontal cortex; GPS1; In situ hybridization; Postmortem; Western blot

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMATE TRANSPORTER; GUANINE NUCLEOTIDE BINDING PROTEIN;

AGED; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN SITU HYBRIDIZATION; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SCHIZOPHRENIA; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AMINO ACID TRANSPORT SYSTEM X-AG; BLOTTING, WESTERN; CELL COMMUNICATION; DNA, ANTISENSE; FEMALE; GENE EXPRESSION PROFILING; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GYRUS CINGULI; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PROTEIN ISOFORMS; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 50249161203     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.06.012     Document Type: Article

References (83)

1. Aanonsen L.M., and Wilcox G.L. Phencyclidine selectively blocks a spinal action of N-methyl-d-aspartate in mice. Neurosci. Lett. 67 2 (1986) 191-197
2. Alfredsson G., and Wiesel F.A. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl.) 99 3 (1989) 322-327
3. Arriza J.L., Eliasof S., Kavanaugh M.P., and Amara S.G. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc. Natl. Acad. Sci. U. S. A. 94 8 (1997) 4155-4160
4. Bertolino A., Callicott J.H., Nawroz S., Mattay V.S., Duyn J.H., Tedeschi G., Frank J.A., and Weinberger D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology 18 1 (1998) 1-9
5. Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., and Wiesel F.A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiatry 147 (1985) 276-282
6. Boston-Howes W., Gibb S.L., Williams E.O., Pasinelli P., Brown Jr. R.H., and Trotti D. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J. Biol. Chem. 281 20 (2006) 14076-14084
7. Bruneau E.G., McCullumsmith R.E., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr. Res. 75 1 (2005) 27-34
8. Burbaeva G., Boksha I.S., Turishcheva M.S., Vorobyeva E.A., Savushkina O.K., and Tereshkina E.B. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 4 (2003) 675-680
9. Callicott J.H., Bertolino A., Egan M.F., Mattay V.S., Langheim F.J., and Weinberger D.R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157 10 (2000) 1646-1651
10. Cartmell J., and Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 75 3 (2000) 889-907
11. Cecil K.M., Lenkinski R.E., Gur R.E., and Gur R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology 20 2 (1999) 131-140
12. Choe B.Y., Kim K.T., Suh T.S., Lee C., Paik I.H., Bahk Y.W., Shinn K.S., and Lenkinski R.E. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad. Radiol. 1 3 (1994) 211-216
13. Clinton S.M., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am. J. Psychiatry 160 6 (2003) 1100-1109
14. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatr. 3 5 (1996) 241-253
15. Crino P.B., Jin H., Shumate M.D., Robinson M.B., Coulter D.A., and Brooks-Kayal A.R. Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy. Epilepsia 43 3 (2002) 211-218
16. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65 1 (2001) 1-105
17. Davis K.E., Straff D.J., Weinstein E.A., Bannerman P.G., Correale D.M., Rothstein J.D., and Robinson M.B. Multiple signaling pathways regulate cell surface expression and activity of the excitatory amino acid carrier 1 subtype of Glu transporter in C6 glioma. J. Neurosci. 18 7 (1998) 2475-2485
18. De Souza I.E., McBean G.J., and Meredith G.E. Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur. J. Pharmacol. 382 2 (1999) 139-142
19. Deicken R.F., Zhou L., Schuff N., and Weiner M.W. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr. Res. 27 1 (1997) 65-71
20. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., and Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin. Neuropharmacol. 12 1 (1989) 1-13
21. Diamond J.S. Neuronal glutamate transporters limit activation of NMDA receptors by neurotransmitter spillover on CA1 pyramidal cells. J. Neurosci. 21 21 (2001) 8328-8338
22. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., and Haroutunian V. N-methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158 9 (2001) 1400-1410
23. Dracheva S., McGurk S.R., and Haroutunian V. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J. Neurosci. Res. 79 6 (2005) 868-878
24. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., and Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 101 34 (2004) 12604-12609
25. Gattaz W.F., Gasser T., and Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol. Psychiatry 20 4 (1985) 360-366
26. Gendreau S., Voswinkel S., Torres-Salazar D., Lang N., Heidtmann H., Detro-Dassen S., Schmalzing G., Hidalgo P., and Fahlke C. A trimeric quaternary structure is conserved in bacterial and human glutamate transporters. J. Biol. Chem. 279 38 (2004) 39505-39512
27. Ghose S., Weickert C.S., Colvin S.M., Coyle J.T., Herman M.M., Hyde T.M., and Kleinman J.E. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29 1 (2004) 117-125
28. Goff D.C., and Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr. Res. 27 2-3 (1997) 157-168
29. Haugeto O., Ullensvang K., Levy L.M., Chaudhry F.A., Honore T., Nielsen M., Lehre K.P., and Danbolt N.C. Brain glutamate transporter proteins form homomultimers. J. Biol. Chem. 271 44 (1996) 27715-27722
30. Hisano S. Vesicular glutamate transporters in the brain. Anat. Sci. Int. 78 4 (2003) 191-204
31. Holleran E.A., Ligon L.A., Tokito M., Stankewich M.C., Morrow J.S., and Holzbaur E.L. beta III spectrin binds to the Arp1 subunit of dynactin. J. Biol. Chem. 276 39 (2001) 36598-36605
32. Huang Y.H., and Bergles D.E. Glutamate transporters bring competition to the synapse. Curr. Opin. Neurobiol. 14 3 (2004) 346-352
33. Huerta I., McCullumsmith R.E., Haroutunian V., Gimenez-Amaya J.M., and Meador-Woodruff J.H. Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse 59 7 (2006) 394-402
34. Itil T., Keskiner A., Kiremitci N., and Holden J.M. Effect of phencyclidine in chronic schizophrenics. Can. Psychiatr. Assoc. J. 12 2 (1967) 209-212
35. Jackson M., Song W., Liu M.Y., Jin L., Dykes-Hoberg M., Lin C.I., Bowers W.J., Federoff H.J., Sternweis P.C., and Rothstein J.D. Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature 410 6824 (2001) 89-93
36. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 10 (1991) 1301-1308
37. Kalandadze A., Wu Y., and Robinson M.B. Protein kinase C activation decreases cell surface expression of the GLT-1 subtype of glutamate transporter. Requirement of a carboxyl-terminal domain and partial dependence on serine 486. J. Biol. Chem. 277 48 (2002) 45741-45750
38. Katsel P., Davis K.L., Gorman J.M., and Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 77 2-3 (2005) 241-252
39. Kegeles L.S., Humaran T.J., and Mann J.J. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol. Psychiatry 44 6 (1998) 382-398
40. Korpi E.R., Kaufmann C.A., Marnela K.M., and Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 20 4 (1987) 337-345
41. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 3 (1994) 199-214
42. Lahti A.C., Holcomb H.H., Medoff D.R., and Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6 6 (1995) 869-872
43. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., and Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 78 2 (2001) 413-416
44. Lauriat T.L., Dracheva S., Chin B., Schmeidler J., McInnes L.A., and Haroutunian V. Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience 137 3 (2006) 843-851
45. Lehre K.P., Levy L.M., Ottersen O.P., Storm-Mathisen J., and Danbolt N.C. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 15 3 Pt 1 (1995) 1835-1853
46. Levenson J., Weeber E., Selcher J.C., Kategaya L.S., Sweatt J.D., and Eskin A. Long-term potentiation and contextual fear conditioning increase neuronal glutamate uptake. Nat. Neurosci. 5 2 (2002) 155-161
47. Lin C.I., Orlov I., Ruggiero A.M., Dykes-Hoberg M., Lee A., Jackson M., and Rothstein J.D. Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18. Nature 410 6824 (2001) 84-88
48. Lin C.L., Tzingounis A.V., Jin L., Furuta A., Kavanaugh M.P., and Rothstein J.D. Molecular cloning and expression of the rat EAAT4 glutamate transporter subtype. Brain Res. Mol. Brain Res. 63 1 (1998) 174-179
49. Liu Y.L., Shen-Jang Fann C., Liu C.M., Wu J.Y., Hung S.I., Chan H.Y., Chen J.J., Lin C.Y., Liu S.K., Hsieh M.H., Hwang T.J., Ouyang W.C., Chen C.Y., Lin J.J., Chou F.H., Chueh C.M., Liu W.M., Tsuang M.M., Faraone S.V., Tsuang M.T., Chen W.J., and Hwu H.G. Evaluation of RGS4 as a candidate gene for schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 4 (2006) 418-420
50. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., and Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res. 32 1 (1990) 63-70
51. Manoach D.S. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr. Res. 60 2-3 (2003) 285-298
52. Masson J., Sagne C., Hamon M., and El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51 3 (1999) 439-464
53. Matute C., Melone M., Vallejo-Illarramendi A., and Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49 3 (2005) 451-455
54. McCullumsmith R.E., and Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 26 3 (2002) 368-375
55. Meador-Woodruff J.H., Davis K.L., and Haroutunian V. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 24 5 (2001) 545-552
56. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., Pellegrini-Giampietro D.E., Rothstein J.D., and Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol. Psychiatry 6 4 (2001) 380-386
57. Nagao S., Kwak S., and Kanazawa I. EAAT4, a glutamate transporter with properties of a chloride channel, is predominantly localized in Purkinje cell dendrites, and forms parasagittal compartments in rat cerebellum. Neuroscience 78 4 (1997) 929-933
58. Ohnuma T., Augood S.J., Arai H., McKenna P.J., and Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res. Mol. Brain Res. 56 1-2 (1998) 207-217
59. Omori M., Pearce J., Komoroski R.A., Griffin W.S., Mrak R.E., Husain M.M., and Karson C.N. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol. Psychiatry 42 5 (1997) 359-366
60. Oni-Orisan A., Kristiansen L.V., Haroutunian V., Meador-Woodruff J.H., and McCullumsmith R.E. Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 63 8 (2008) 766-775
61. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 28 1 (1982) 81-85
62. Quintana J., Wong T., Ortiz-Portillo E., Marder S.R., and Mazziotta J.C. Anterior cingulate dysfunction during choice anticipation in schizophrenia. Psychiatry Res. 132 2 (2004) 117-130
63. Rajkowska G., and Goldman-Rakic P.S. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb. Cortex 5 4 (1995) 307-322
64. Robinson M.B. The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. Neurochem. Int. 33 6 (1998) 479-491
65. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P., and Welty D.F. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16 3 (1996) 675-686
66. Saransaari P., Lillrank S.M., and Oja S.S. Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations. J. Neural Transm. Gen. Sect. 93 1 (1993) 47-59
67. Smith R.E., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry 158 9 (2001) 1393-1399
68. Smith R.E., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport 12 13 (2001) 2885-2887
69. Spain B.H., Bowdish K.S., Pacal A.R., Staub S.F., Koo D., Chang C.Y., Xie W., and Colicelli J. Two human cDNAs, including a homolog of Arabidopsis FUS6 (COP11), suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction in yeast and mammalian cells. Mol. Cell Biol. 16 12 (1996) 6698-6706
70. Stan A.D., Ghose S., Gao X.M., Roberts R.C., Lewis-Amezcua K., Hatanpaa K.J., and Tamminga C.A. Human postmortem tissue: what quality markers matter?. Brain Res. 1123 1 (2006) 1-11
71. Stankewich M.C., Tse W.T., Peters L.L., Ch'ng Y., John K.M., Stabach P.R., Devarajan P., Morrow J.S., and Lux S.E. A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. Proc. Natl. Acad. Sci. U. S. A. 95 24 (1998) 14158-14163
72. Steel R.M., Bastin M.E., McConnell S., Marshall I., Cunningham-Owens D.G., Lawrie S.M., Johnstone E.C., and Best J.J. Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res. 106 3 (2001) 161-170
73. Tamminga C. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry Suppl(37) (1999) 12-15
74. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., and Carpenter W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry 49 7 (1992) 522-530
75. Tanaka K., Watase K., Manabe T., Yamada K., Watanabe M., Takahashi K., Iwama H., Nishikawa T., Ichihara N., Kikuchi T., Okuyama S., Kawashima N., Hori S., Takimoto M., and Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276 5319 (1997) 1699-1702
76. Utsunomiya-Tate N., Endou H., and Kanai Y. Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter. J. Biol. Chem. 271 25 (1996) 14883-14890
77. van Holde K.E. Physical Biochemistry (1985), Prentice-Hall, Inc., Englewood Cliffs, NJ
78. Varoqui H., Schafer M.K., Zhu H., Weihe E., and Erickson J.D. Identification of the differentiation-associated Na+/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J. Neurosci. 22 1 (2002) 142-155
79. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., Nord A.S., Kusenda M., Malhotra D., Bhandari A., Stray S.M., Rippey C.F., Roccanova P., Makarov V., Lakshmi B., Findling R.L., Sikich L., Stromberg T., Merriman B., Gogtay N., Butler P., Eckstrand K., Noory L., Gochman P., Long R., Chen Z., Davis S., Baker C., Eichler E.E., Meltzer P.S., Nelson S.F., Singleton A.B., Lee M.K., Rapoport J.L., King M.C., and Sebat J. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320 5875 (2008) 539-543
80. Watanabe M., Robinson M.B., Kalandadze A., and Rothstein J.D. GPS1, interacting protein with GLT-1. Program No. 372.16 2003 SFN Abstract (2003)
81. Watanabe M., Ueki T., Jackson M., Ruggiero A.M., Sawa A., Kalandadze A., Robinson M.B., and Rothstein J.D. CSN1 Downregulates GLT-1 activity. SFN Abstract (2004)
82. Williams S.M., Sullivan R.K., Scott H.L., Finkelstein D.I., Colditz P.B., Lingwood B.E., Dodd P.R., and Pow D.V. Glial glutamate transporter expression patterns in brains from multiple mammalian species. Glia 49 4 (2005) 520-541
83. Yamada K., Watanabe M., Shibata T., Tanaka K., Wada K., and Inoue Y. EAAT4 is a post-synaptic glutamate transporter at Purkinje cell synapses. Neuroreport 7 12 (1996) 2013-2017